Acadia Pharma (ACAD) Q2 Revs of $115.2M; Tops EPS by 4c
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $25.77 -0.77%
EPS Growth %: -62.5%
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
CRMT, PKE, More
EPS Growth %: -62.5%
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
CRMT, PKE, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q2 EPS of ($0.27), $0.04 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $115.2 million versus the consensus estimate of $126.15 million.
GUIDANCE:
Acadia Pharma sees Q3 2021 revenue of $480-515 million, versus the consensus of $527.7 million.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Morgan Stanley Resumes Gap, Inc. (GAP) at Equalweight
- Morgan Stanley turns cautious on freight stocks despite stronger cycle outlook
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
